Is Home Depot Stock A Buy Right Now After Q4 Earnings? Here's What Earnings, Charts Show
Home Depot is one of the biggest companies in the United States and a stock leader on the Dow Jones industrials, but is Home Depot stock a buy right now?
It was an issue before the COVID crisis, and it is proving to be an even bigger problem today.
Power grid operator Electric Reliability Council of Texas (ERCOT) made a $16 billion pricing error in the week of the winter storm that led to power outages across Texas, Potomac Economics, which monitors the state's power market, said. ERCOT kept market prices for power too high for more than a day after widespread outages ended late on Feb. 17, Potomac Economics, the independent market monitor for the Public Utility Commission of Texas, which oversees ERCOT, said in a filing.
Mexico's government has walled off the presidential palace with a metallic barrier ahead of a planned women's march on Monday to protest rampant violence against women and the president's support for a gubernatorial candidate accused of rape. Barriers were also installed around other emblematic buildings and monuments in downtown Mexico City where a year ago tens of thousands of people marched on International Women's Day, the vast majority peacefully. "It is outrageous, few people support us in the cry for justice," said Becky Bios, who survived an attempted femicide -- a term for gender-driven killing -- in 2015 and will participate in the march.
The US Senate broke a logjam late Friday when a centrist Democrat compromised on a key provision of the Covid relief package, setting the $1.9 trillion bill on a likely path to passage.
A batch of the Queensland milk has been recalled after an E.coli contamination was found.
RADNOR, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of New York against MultiPlan Corporation (NYSE: MPLN; MPLN.WS) (“MultiPlan”) f/k/a Churchill Capital Corp. III (“Churchill III”) on behalf of: (1) those who purchased or acquired MultiPlan securities between July 12, 2020 and November 10, 2020, inclusive (the “Class Period”); and (2) all holders of Churchill III Class A common stock entitled to vote on Churchill III’s merger with and acquisition of Polaris Parent Corp. and its consolidated subsidiaries consummated in October 2020 (the “Merger”). Deadline Reminder: Investors who purchased or acquired MultiPlan securities during the Class Period may, no later than April 26, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com; or click https://www.ktmc.com/multiplan-corp-securities-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=multiplan. Churchill III was formed in October 2019 as a special purpose acquisition vehicle. On February 14, 2020, Churchill III completed its initial public offering, selling 110 million ownership units to investors for gross proceeds of $1.1 billion (the “IPO”). Pursuant to the IPO prospectus, Churchill III was required to acquire a target business with an aggregate fair market value of at least 80% of the assets held in trust from the IPO proceeds and to do so within two years of the IPO. The Class Period commences on July 12, 2020, when Churchill III and MultiPlan, a healthcare cost specialist, issued a joint press release announcing their agreement to combine. The Merger, initially valued at $5.7 billion, would be funded by the IPO proceeds as well as billions of dollars in new debt and equity issuances. On September 18, 2020, Churchill III issued the proxy statement for the Merger which urged shareholders to vote in favor of the deal (the “Proxy”). The Proxy stated that Churchill had identified MultiPlan as a potential acquisition target soon after the IPO. On the basis of the Proxy, on October 7, 2020, shareholders voted to approve the Merger at a special shareholders meeting. Because of the Proxy, shareholders were prevented from the fully informed opportunity to redeem their shares as was their right. The shares subject to redemption were valued in the Proxy at approximately $10 per share. On November 11, 2020, one month after the close of the Merger, Muddy Waters published a report on Churchill III titled “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab”, which was based on extensive non-public sources such as interviews with former MultiPlan executives and other industry experts, as well as proprietary analysis. The report revealed, in part, that: (1) MultiPlan was in the process of losing its largest client, UnitedHealthcare, which was estimated to cost Churchill III up to 35% of its revenues and 80% of its levered free cash flow within two years; (2) MultiPlan was in significant financial decline because of its fundamentally flawed business model, which profited from excessively high healthcare costs; (3) UnitedHealthcare had purportedly launched a competitor, Naviguard, to reduce its business with MultiPlan and bring the over-priced and conflicted services offered by MultiPlan inhouse; and (4) MultiPlan had suffered from material, undisclosed pricing pressures that had caused it to slash the “take rate” it charged customers in half in some instances and falsely characterized revenue declines as “idiosyncratic” when in fact they were due to sustained, negative pricing trends afflicting MultiPlan’s business. Following this news, the price of Churchill III’s securities declined. By November 12, 2020, the price of Churchill III’s Class A common stock fell to a low of just $6.12 per share, nearly 40% below the price at which shareholders could have redeemed their shares at the time of the shareholder vote on the Merger. The complaint alleges that the Proxy failed to disclose among other things that: (a) MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, which threatened up to 35% of Churchill III’s sales and 80% of its levered cash flows by 2022; (b) sales and revenue declines in the quarters leading up to the Merger were not due to “idiosyncratic” customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan’s services and increased competition; (c) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers; (d) as a result of the foregoing, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; and (e) as a result of the foregoing, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan’s business was worth far less than represented to investors. MultiPlan investors may, no later than April 26, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)(610) 667-7706info@ktmc.com
Jason Day found a birdie he'd rather not have during a cruel round that left Australia's former world No.1 playing catch-up at the Arnold Palmer Invitational.
The post, sent from Dorsey's account in March of 2006, received offers on Friday that went as high as $88,888.88 within minutes of the Twitter co-founder tweeting a link to the listing on 'Valuables by Cent' - a tweets marketplace. Old offers for the tweet suggest that it was put for sale in December, but the listing gained more attention after Dorsey's tweet on Friday.
At least 30,000 US organizations including local governments have been hacked in recent days by an "unusually aggressive" Chinese cyber-espionage campaign, according to a computer security specialist.
Former number one NBA draft pick Blake Griffin has reached a buyout deal with the Detroit Pistons and will become an unrestricted free agent, the team announced on Friday.
A key Muslim organisation is urging the New Zealand government to smarten up intelligence services in the wake of an online threat to attack mosques in Christchurch using carbombs.A 27-year-old man was arrested and charged for the shocking pledge this week, less than a fortnight from the second anniversary of the Christchurch Mosque terror attacks.
The couple are among more than 40,000 Aussies stranded overseas – so they took to the internet to find a solution.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against 3D Systems Corporation (NYSE: DDD) on behalf of 3D Systems stockholders. Our investigation concerns whether 3D Systems has violated the federal securities laws and/or engaged in other unlawful business practices.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Leidos Holdings, Inc. (NYSE: LDOS) securities between May 4, 2020 and February 23, 2021, inclusive (the "Class Period"). Investors have until May 3, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Tricida, Inc. (NASDAQ: TCDA) securities between September 4, 2019 and October 28, 2020 (the “Class Period”). Investors have until March 8, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Tricida is a pharmaceutical company that focuses on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally administered polymer designed as a potential treatment for metabolic acidosis in patients with CKD. Tricida has completed a Phase 3, double-blind, placebo-controlled trial of veverimer in patients with CKD and metabolic acidosis. On September 4, 2019, Tricida announced that it had submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) under the Accelerated Approval Program for approval of veverimer for the treatment of metabolic acidosis in patients with CKD. On July 15, 2020, Tricida issued a press release announcing that, on July 14, 2020, the Company received a notification from the FDA, stating that as part of the FDA’s ongoing review of the Company’s NDA for veverimer, “the FDA has identified deficiencies that preclude discussion of labeling and post marketing requirements/commitments at this time.” Tricida stated that “[t]he notification does not specify the deficiencies identified by the FDA.” On this news, Tricida’s stock price fell $10.56 per share, or 40.31%, to close at $15.64 per share on July 16, 2020. Then, on October 29, 2020, Tricida announced an update on its End-of-Review Type A meeting with the FDA regarding the veverimer NDA, advising investors that the Company “now believes the FDA will also require evidence of veverimer’s effect on CKD progression from a near-term interim analysis of the VALOR-CKD trial for approval under the Accelerated Approval Program and that the FDA is unlikely to rely solely on serum bicarbonate data for determination of efficacy.” Concurrently, Tricida disclosed that it “is significantly reducing its headcount from 152 to 59 people and will discuss its commitments with vendors and contract service providers to potentially provide additional financial flexibility.” On this news, Tricida's stock price fell $3.90 per share, or 47.16%, to close at $4.37 per share on October 29, 2020. The complaint, filed on January 6, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and failed to disclose to investors that: (i) Tricida’s NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. If you purchased Tricida securities during the Class Period and suffered a loss, are a long-term stockholder have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Baker Hughes Company (NYSE: BKR) on behalf of Baker Hughes stockholders. Our investigation concerns whether Baker Hughes has violated the federal securities laws and/or engaged in other unlawful business practices.
As Pope Francis prays for Iraq's minorities Saturday from the birthplace of the common patriarch of the Christian, Jewish and Muslim faiths, one family will be listening particularly carefully.
Tasmania have ended Peter Handscomb's gritty knock with the Victorians 6-130 at lunch on day two of their Sheffield Shield clash at the MCG.Resuming on 52 on Saturday with the Vics 3-70 in reply to the visitors' first innings total of 188, the Victorian skipper was unable to press on to record a 16th first-class century.
Venezuela's central bank said on Friday that it would introduce a banknote worth 1 million bolivars beginning next week, as years of incessant hyperinflation continue to batter the value of the crisis-stricken South American country's currency. The new banknote will be worth just 52 U.S. cents at the current official exchange rate. Interannual inflation was running at 2,665% as of January, according to the central bank.
Sri Lanka's spinners bamboozled world champions West Indies to claim a 43-run win in the second Twenty20 International at Coolidge Cricket Ground on Friday.